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Medizinische Hochschule, 30625 Hannover, GermanyHepatitis C virus (HCV) is a blood borne disease estimated to Introduction
chronically infect 3% of the worlds’ population causing signiﬁcant
morbidity and mortality. Current medical therapy is curative in
approximately 50% of patients. While recent treatment advances
of genotype 1 infection using directly acting antiviral agents
(DAAs) are encouraging, there is still a need to develop vaccine
strategies capable of preventing infection. Moreover, vaccines
may also be used in future in combination with DAAs enabling
interferon-free treatment regimens.
Viral and host speciﬁc factors contribute to viral evasion and
present important impediments to vaccine development. Both,
innate and adaptive immune responses are of major importance
for the control of HCV infection. However, HCV has evolved ways
of evading the host’s immune response in order to establish per-
sistent infection. For example, HCV inhibits intracellular inter-
feron signalling pathways, impairs the activation of dendritic
cells, CD8+ and CD4+ T cell responses, induces a state of T-cell
exhaustion and selects escape variants with mutations CD8+ T
cell epitopes. An effective vaccine will need to produce strong
and broadly cross-reactive CD4+, CD8+ T cell and neutralising
antibody (NAb) responses to be successful in preventing or clear-
ing HCV.
Vaccines in clinical trials now include recombinant proteins,
synthetic peptides, virosome based vaccines, tarmogens, modi-
ﬁed vaccinia Ankara based vaccines, and DNA based vaccines.
Several preclinical vaccine strategies are also under development
and include recombinant adenoviral vaccines, virus like particles,
and synthetic peptide vaccines. This paper will review the vac-
cines strategies employed, their success to date and future direc-
tions of vaccine design.
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als) and causes an estimated 476,000 deaths per year as a result
of HCV-associated end-stage liver disease and its complications
[1,26,131]. Signiﬁcant advances have been made in the treatment
of both acute [65,153] and chronic hepatitis C infection
[46,55,92,96,158]. With the recent development of directly acting
antiviral agents (DAAs) for HCV, signiﬁcant improvements in sus-
tained virological response rates are now possible for patients
infected with HCV genotype 1 [94,141]. However, even during
the next many years treatment will still be based on the admin-
istration of interferon alpha and ribavirin [98] which is not only
expensive but also associated with a substantial number of side
effects. Overall, only a small minority of patients with chronic
hepatitis C can currently be cured in most real-world settings
with interferon-based treatments [40].
An effective preventive vaccine would considerably reduce
the number of new infections and thereby reduce the burden
on health care systems. However, there are many impediments
to the development of a vaccine for HCV including the existence
of multiple HCV genotypes, limited availability of animal models
and the complex nature of the immunological response to HCV.
Clearance of hepatitis C infection requires strong and broadly
cross-reactive CD4+, CD8+ T cell [80,130,132] and neutralising
antibody (NAb) responses [114].
The development of a multi-speciﬁc T cell response during
acute HCV infection is associated with the spontaneous clearance
of infection [133] and may provide a level of protection against
reinfection [51]. It is also apparent that neutralising antibody is
protective and associated with the rapid clearance of hepatitis
C viraemia [83,114]. Reinfection among individuals who are
repeatedly exposed to HCV, such as injecting drug users (IDU),
however, raises concerns that the development of long-term pro-
tective immunity for HCV may not be possible [147]. However,
cohort studies in IDUs are not able to completely assess the num-
ber of episodes of viral clearance compared to persistence [52].
We know that spontaneous recovery does occur in the setting
of a successful immune response against HCV [80,87,138] and
although the correlates of protective immunity are not com-
pletely understood the development of an effective vaccine for
HCV should be achievable, as supported by vaccination studies
performed in chimpanzees [61].11 vol. 54 j 1273–1285
Fig. 1. Summary of the immune responses required to clear HCV and the major sites of action of different HCV preventive and therapeutic vaccines.
ReviewSeveral approaches to HCV vaccine development have now
been studied and include recombinant E1 and E2 proteins [22],
synthetic peptides [38,72,151], DNA [119], and prime-boost
strategies [43] (Fig. 1). Success of these approaches has been lim-
ited for a number of reasons including: the delivery of a limited
number of protective viral epitopes, the inclusion of incorrectly
folded recombinant proteins, the limited humoral and cell medi-
ated responses that are associated with DNA vaccines, and the
use of adjuvants with relatively poor potency. It is also now
apparent that vaccine inducing strong T cell responses alone
may not be sufﬁcient to prevent hepatitis C infection [119]. An
effective preventive vaccine against HCV will, therefore, need to
induce strong neutralising and cellular immune responses.Correlates of hepatitis C cell mediated immunity
It is apparent that clearance of hepatitis C infection requires early
and multi-speciﬁc class 1 restricted CD8+ T cell [28,87,104,132,
133,138,142] and class II restricted CD4+ T cell [31,50,77,130]
responses to both structural and non-structural HCV proteins
(Table 1)(Fig. 1). Clearance of HCV and protection from reinfec-
tion is determined not only by the magnitude and/or breadth of
multifunctional CD8+ T cells but also by the quality, functional
potency, and cytotoxic potential of HCV-speciﬁc CD8+ T cells1274 Journal of Hepatology 2011[14,80–82] and the selection of high-avidity CD8+ T cells [110]
which respond to a diverse array of HLA-class I restricted HCV-
core, E1, NS3, NS4, and NS5 epitopes [14,20,21,80–82,127]. Stud-
ies in chimpanzees have also shown that it is possible to induce
memory responses that are protective against reinfection [30].
The ability to produce strong HCV speciﬁc CD8+ and CD4+ T cell
responses are important considerations for effective HCV vaccine
design. It may also be important to consider the differences that
exist in CD8+ T cell speciﬁcities in peripheral compared to intra-
hepatic CD8+ T cells [45,74,108,154].
The relative contributions of individual viral proteins to the
total magnitude of the HCV-speciﬁc CD4+ and CD8+ T cell
responses also play an important role in determining the out-
come of infection. Using various approaches it has been possible
to determine a hierarchy of CD4+ and CD8+ T cell responses, par-
ticularly to the NS3 protein [80,130,137,152]. It is also possible to
elicit strong HCV core speciﬁc CD4+ and CD8+ T cell responses in
naïve human lymphocytes [89]. These studies argue that the
inclusion of CD8+ T cell epitopes representing key viral proteins,
like core and NS3, will be essential for the development of a cell
mediated vaccine for HCV. However, a recent meta-analysis of
the efﬁcacy of HCV vaccines in chimpanzees has shown that
the inclusion of structural proteins in vaccines was more signiﬁ-
cantly associated with protective immune responses compared to
vaccines based on non-structural proteins of HCV [30].vol. 54 j 1273–1285
Table 1. Summary of the correlates of protective HCV immunity and the mechanisms of viral evasion of immune responses.
Correlates of protective immunity 
Neutralising antibodies to linear epitopes E1 and E2 glycoproteins 
Neutralising antibodies to conformational  epitopes in E2 (AR3) 
Broad and strong CD8+ T cell responses to NS3>core>NS4>NS5 
Strong cytotoxic T cell response 
Strong CD4+ T cell responses  
Mechanisms of viral immune evasion 
Viral factors
Existence of viral quasispecies
Impairment of DC maturation
Inhibition of interferon-γ response 
Viral CD4+ escape mutants
Viral CD8+ escape mutants 
T cell exhaustion (e.g. upregulation of PD1 
        and other molecules) 
Humoral antibody escape: 
HDL/SR-B1 interactions
Glycan interference 
Interfering antibody epitopes
Host factors
MHC Class I restriction
Limited TCR repertoire
IL28B gene polymorphisms  
JOURNAL OF HEPATOLOGYNeutralising antibody (NAb) responses to HCV and
neutralising epitope domains
A strong line of evidence now exists demonstrating that NAb
responses to epitopes in the viral E1 and E2 glycoproteins can be
protective [155] and is associated with resolution of hepatitis C
infection [114]. Vaccination of chimpanzees with mammalian
cell, but not yeast cell-derived recombinant HCV E1 and E2 glyco-
proteins has been shown to prevent the development of chronic
infection with both homologous and heterologous viruses
[22,25,60,73,124]. Similarly, neutralisation of a viral inoculumwith
either rabbit hyperimmune serum directed to homologous virus
[37] or human anti-HCV sera [38] and immunoglobulin [155] pro-
tected chimpanzees against viral challenge, thus providing strong
evidence that NAb contributes to protection against HCV.
E2 neutralising epitopes
Distinct neutralizing antibody epitopes have been identiﬁed in
hypervariable region 1 (HVR1) of the E2 protein [37,38,62,
88,124] and in the region downstream of HVR1, including the
binding sites for the putative HCV receptor, CD81
[8,53,62,68,84,143,144]. Also, epitopes in the amino-terminus of
HVR1 may induce neutralising antibody responses that are
associated with self-limiting hepatitis C infection [160]. In con-
trast, antibodies to the carboxy-terminal end of HVR1 may not
be neutralising and may represent epitopes that interfere with
the optimal development of neutralising antibody response [36].
It is now apparent that epitopes within E2 can be broadly
cross neutralising [136], some of which do not overlap with the
CD81 binding domain of the E2 protein [53,143]. Also, monoclo-
nal antibodies directed to a conserved conformational region of
the E2 protein that is known to contain a major neutralising anti-
genic region referred to as antigenic region 3 (AR3) [84] of HCV
genotype 1a virus are able to cross neutralise HCV of different
genotypes. AR3 is located on the viral envelope and is formed
by three discontinuous segments situated between amino acidsJournal of Hepatology 2011396–434, 436–447, and 523–540 of the E2 protein (Fig. 2). Impor-
tantly, passive immunization of human liver chimeric Alb-uPA/
SCID mice with monoclonal antibodies directed to AR3 protect
these mice against challenge with human serum derived HCV,
further highlighting the importance of effective NAb and the sig-
niﬁcance of delivering HCV neutralising epitopes in the correct
conformation [84]. It should, therefore, be possible to develop
an effective vaccine strategy that will include conserved neutral-
ising epitopes outside of HVR1, and a HCV VLP based vaccine has
the very real potential to achieve this goal.E1 neutralising epitopes
Less is known about neutralising immune responses to the E1
glycoprotein of HCV and until recently there have been relatively
few reports describing neutralising epitopes contained within E1
[53,101,143]. However, a broadly cross-neutralising epitope has
been identiﬁed between amino acids 313–327 of a highly con-
served region of the E1 protein [101,143] (Fig. 2). Monoclonal
antibodies directed to this epitope strongly neutralise HCV/HIV
pseudotypic particles bearing the envelope glycoproteins of
HCV genotypes 1a, 1b, 4a, 5a, and 6a and less so against 2a and
2b. These monoclonal antibodies also neutralised cell culture
derived HCV of genotypes 1a and 2a. In addition, it has also been
shown that cross-neutralizing E1-speciﬁc antibodies can be pro-
duced following vaccination of mice with a retrovirus-based HCV
virus like particle vaccine [33,116] highlighting the importance of
including E1 in a preventive HCV vaccine.Viral entry
The entry of HCV into hepatocytes is dependent on a complex
series of interactions between the virus and a number of cell
surface proteins including the LDL receptor [9,34,57], the tetra-
spanin CD81 [97,99], SR-B1 [33,57] and the tight junction
proteins Claudin 1 and Occludin [115,117]. Antibodies that blockvol. 54 j 1273–1285 1275
ETHVYGGSAGRTTAGLVGLLTPGAKQN
432SLNTGWLAGLFY443
436GWLAGLFYQHKF447
QLINTNGSWHIN
TAGLVGLLTPGA
396TAGLVGLLTPGAKQNIQLINTNGSWHINS424 523GAPTYSWGANDTDVFVLN540
313ITGHRMAWDMMMNWS327
309YPGHITGHRMAWDMMMNW326
610DYPYRLWHYPCTINYTIF627
631MYVGGVEHRLEAACNWTR648
192 354 383
384 396 407 414 431 466 474 482 718 746
412 423
E1 E2TMD TMDHVR1 HVR2HVR3
AR3
Fig. 2. Summary of neutralizing domains described in both the E1 and E2 proteins. AR3 is formed by three discontinuous epitopes on the viral envelope.
Reviewthe binding of HCV to CD81, SR-B1, or Claudin 1 reduce the entry
of cell culture derived HCV into hepatocytes. However, by com-
bining antibodies speciﬁc for Claudin 1, SR-B1, and CD81 almost
completely abolished viral entry [75]. These ﬁndings demonstrate
the complex nature of HCV neutralization and serve to highlight
that for a preventive neutralizing strategy to be effective it will
need to target several key domains on the viral envelope.1276 Journal of Hepatology 2011Evasion of the immune responses by HCVHepatitis C virus has evolved several ways of evading the host’s
immune response in order to establish persistent infection [15–
17,47,50,103,113,149] (Table 1). HCV exists as a population of
closely related viral quasi-species that are sufﬁciently distinct
immunologically to enable emerging HCV variants to elude the
host humoral and cellular immune responses [17]. The virus is
also able to modulate the host antiviral cytokine response by
inhibiting intracellular antiviral interferon signalling pathways
[15,103].
HCV also impairs the activation of dendritic cells (DC)
although this has not been a consistent ﬁnding
[4,5,18,24,66,126]. DC isolated from patients chronically infected
with HCV are able to mature normally in response to HCV lipo-
peptides [23] and DC from chimpanzees chronically infected with
HCV are not functionally impaired [79]. In contrast, both CD8+
and CD4+ T cell responses are impaired by HCV. Hepatitis C
virus-speciﬁc CD8+ T cells from patients with chronic hepatitis
C have impaired effector function [149]. In addition, HCV upreg-
ulates the expression of PD-1 on peripheral and intrahepatic CD8+
T cells resulting in T-cell exhaustion [106,113,120] while block-
ade of PD-1 is associated with a functional restoration of CD8+
T cell function in HCV [106]. Differential expression of several
other co-stimulatory and co-inhibitory receptors on virus-spe-
ciﬁc CD8+ T cells may also further inﬂuence T cell responses.
Examples include CTL-A4 [106] 2B4 (CD244) [129] or CD86
[121]. These may all have important implications for the design
of an effective therapeutic HCV vaccine as the primary vaccine
recipients will be patients with chronic infection in whom signif-
icant abnormalities of T cell function already exist.vol. 54 j 1273–1285
Table 2. Summary clinical trials with preventive and therapeutic vaccines for HCV.
N
Prophylactic 
vaccine  
Therapeutic 
vaccines
Pevion Biotech Ltd 
Intercell AG 
Intercell AG 
Innogenetics / 
GenImmune 
GlobeImmune 
GlobeImmune
pepirT
Transgene
Immunogenicity
Induce HCV-specific 
T cell responses 
Weak reduction in 
viral load 
HCV-specific T cell 
responses
tneitapenoylno
experiencing a one-
log10 reduction in 
viral load 
Induce both humoral 
and cellular immune 
responses against 
HCV E1 
Reduction in ALT 
compared with 
placebo and 
reduction in viral 
load to -1.4 log 
ETR 74% vs 59% 
for standard of care 
therapy. SVR 58% 
vs 48% for standard 
of care therapy  
Safe, immunogenic 
and  transient 
effects on viral load 
T cell responses
(detected by ELISpot 
IFN-γ) and viral load
reduction up to 
devresbogol5.1
Challenge 
inoculum
inoculum
Recombinant E1 
and E2 proteins
Virosome-formulated
peptides (CD4 and CD8 
components) 
IC41  
HCV peptide 
vaccine with 
polyarginine
IC41 
HCV peptide 
vaccine with 
polyarginine 
135aa C-terminally 
truncated recombinant 
form of E1 protein, 
formulated on 
alum 
GI-5005; an 
inactivated recombinant 
Saccharomyces cerevisiae
expressing a hepatitis C 
virus NS3-Core  
nietorpnoisuf
GI-5005 combined 
with pegylated Interferon 
plus Ribavirin 
DNA based vaccine 
CHRONVAC-C  ®
in combination with 
electroporation
TG4040 MVA 
virus carrying and 
expressing non-structural
proteins (NS3, NS4 and 
NS5B)
Outcome
Trial 
completed 
data not yet 
published 
Ongoing- not 
, atadgnitiurcer
not published 
Completed
Trial ongoing 
not recruiting
2 placebo 
controlled 
trials completed; 
program stopped 
as no effect on 
fibrosis progression 
was detected
ongoing 
ongoing 
Recruiting 
patients 
Recruiting 
patients 
Phase I - IV
Phase I 
randomized, 
observer -
blinded, 
placebo-
controlled study
Phase I  
Phase II 
Phase II 
Phase IIb
Phase I 
Phase II 
Phase I/IIa 
Phase I 
Registration 
Immunogenicity Challenge Outcome Phase I - IV Registration 
number* 
number* 
NCT00500747
NCT00445419
CT00602784
NCT00601770
NCT00124215
NCT00606086
NCT00563173
NCT00529321
Chiron Corp HCV
E1/E2 Vaccine
⁄Prophylactic and therapeutic trials registered with clinicaltrials.gov.
JOURNAL OF HEPATOLOGYFurther mechanisms to evade the host immune response
include the selection of escape variants that carry mutations in
key CD8+ T cell epitopes [16,107,145] or through the restriction
of T-cell receptor repertoires [102] thereby impairing viral spe-
ciﬁc CD8 responses.Journal of Hepatology 2011In addition to escaping cellular immune responses HCV has
also evolved several mechanisms to evade humoral responses.
These include the association of HCV with high-density lipopro-
tein [33,148] leading to the interference of binding of neutralising
antibody to HCV. The HDL mediated interference of neutralisationvol. 54 j 1273–1285 1277
Review
results from a complex interplay with the cell surface protein
Scavenger Receptor-B1 (SR-B1) and enhanced viral entry into
hepatocytes [10]. The viral envelope is also heavily glycosylated
and the presence of these glycans protects the virus against the
development and binding of neutralising antibodies [58,91].
Finally, it has also been reported that some sequences in the C-ter-
minal region of HVR1, (amino acids 434–446) may interfere with
protective neutralizing antibody responses, providing the virus
with another mechanism to evade protective antibody responses
[159].
Finally, the ability to clear hepatitis C infection spontaneously
and following antiviral treatment may be genetically predeter-
mined, as shown by the high rate of spontaneous clearance of
acute hepatitis C infection and the high sustained virological
response rates following treatment with pegylated interferon
plus ribavirin in association with speciﬁc polymorphisms of the
IL28B gene [48,122,135,139]. The presence of such genetically
predetermined antiviral responses may also have a signiﬁcant
impact on the host’s ability to develop protective immune
responses following vaccination, adding yet another layer of com-
plexity to the design of an effective vaccine for HCV.HCV vaccines in clinical trials
Preventive HCV vaccines
Recombinant proteins
Recombinant envelope glycoprotein’s were amongst the earliest
preventive vaccine candidates for HCV but relatively few have
entered into clinical trials. One such vaccine candidate includes
the envelope gpE1/gpE2 proteins in an oil water adjuvant MF59
together with a CpG oligonucleotide (Chiron Corp) [61,146]. This
vaccine has entered into a Phase I randomized, observer-blinded,
placebo-controlled study and was registered with clinicaltri-
als.gov on July 12, 2007. This trial will evaluate the safety, toler-
ability and immunogenicity of the HCV E1E2/MF59 vaccine in
healthy HCV-negative adults. The study has been completed
but not reported to date (Table 2).
In another approach a yeast derived recombinant HCV core
protein adjuvanted with ISCOMATRIX has been studied in a Phase
I placebo controlled, dose escalation clinical study of the safety of
the vaccine in 30 human participants. Antibody responses were
detected in all but one of the participants. In contrast, CD8+ T cell
responses were only detected in two of the thirty participants
and T cell cytokines were detected in 7 of the 8 participants in
the highest dose group [32].
Therapeutic HCV vaccines
Approaches that aim to increase HCV speciﬁc cell-mediated
responses may improve the likelihood of achieving a sustained
virological response and therapeutic vaccines may provide a
means of achieving this goal. The concepts underlying therapeu-
tic vaccines can be divided into three major strategies; (i) com-
bining a therapeutic vaccine with antiviral therapies to
enhancing anti-HCV immunity with the major aim of preventing
viral relapse after stopping antiviral therapy, (ii) treating ﬁrst
with a therapeutic vaccine to induce HCV-speciﬁc immune
responses followed by antiviral treatment in order to maximise
early viral suppression and thereby increase sustained virological1278 Journal of Hepatology 2011response rates, (iii) using therapeutic vaccination to produce par-
tial control of HCV infection without inducing HCV clearance.
Several therapeutic vaccine strategies have been explored and
although these have provided promising results to date they have
had limited success in clearing infection. Consequently, studies to
investigate their role as an adjunct to pegylated interferon/ribavi-
rin therapy have now commenced.Synthetic peptide vaccines
IC41 (Intercell)
The IC41 vaccine (Intercell AG, Vienna, Austria) contains ﬁve syn-
thetic peptides encoding for four HCV speciﬁc HLA-A2 restricted
CTL epitopes (core35–44 and 132–140, NS3 1073–1081, NS4
1764–1772) and three highly promiscuous CD4+ T cell epitopes
(core23–44, NS3 1248–1261, NS4 1767–1786) that have been
adjuvanted with poly-L-arginine to augment Th1/Tc1 (IFN-
gamma) responses (Fig. 1). The sequences contained within these
epitopes are highly conserved in the most prevalent HCV geno-
types 1a, 1b, and 2.
The immunogenicity of IC41 with or without poly-L-arginine
was initially investigated in a randomized, placebo controlled
trial [41]. Although half of the recipients experienced local injec-
tion site reactions the vaccine was well tolerated. A dose depen-
dent proliferative CD4+ and CD8+ T cell response was induced in
the majority of vaccine recipients. Furthermore, the inclusion of
poly-L-arginine was shown to be important for the production
of functional interferon-c secreting T cells [41].
A subsequent randomized double-blind phase II studywas per-
formed in sixty HLA-A2-positive chronic HCV patients who had
either relapsed or failed to respond to previous pegylated inter-
feron/ribavirin therapy [71]. The vaccine was well tolerated with
themost common adverse events in the vaccine recipients includ-
ing local reactions and inﬂuenza-like illness. Over two thirds of
patients developed HCV-speciﬁc Th1/Tc1 responses and one third
developed sustained T cell responses lasting up to sixmonths after
the last vaccination. However, responses were generally weak
with viremia persisting in all recipients and only one patient expe-
riencing a one-log10 reduction in viral load (Table 2)[71].
Based on the premise that IC41 is able to induce HCV speciﬁc
T cell responses, the role of IC41 as an adjunctive add-on immu-
notherapy to treatment with pegylated interferon/ribavirin has
also recently been investigated in a phase II trial [151]. Thirty-ﬁve
HLA A2 positive patients infected with HCV genotype 1 were
given six doses of IC41 from weeks 24 to 48 of pegylated inter-
feron/ribavirin treatment and followed for a further six months.
Vaccination did not decrease the virological relapse rate although
those who developed sustained virological responses also devel-
oped strong HCV-speciﬁc responses (Table 2) [151].
An optimized vaccine schedule was subsequently tested in
healthy volunteers. Of note, bi-weekly intradermal injections of
IC41 induced much stronger T cell responses than the initial
monthly subcutaneous vaccination [42]. This improved vaccine
schedule was tested in 50 patients with chronic hepatitis C and
resulted in a signiﬁcant decline in viral load after 4 months of
biweekly therapeutic vaccination [70]. This study provided proof
of concept that therapeutic vaccination aimed at inducing HCV
speciﬁc T cell responses is able contribute to the control of HCV
infection.
Recently, a group of investigators from Japan reported phase I
dose-escalation study to assess the safety and immune responsesvol. 54 j 1273–1285
JOURNAL OF HEPATOLOGY
to the HLA-A2-restricted HCV core peptide YLLPRRGPRL in 25
HCV-positive patients [156]. The vaccine was well tolerated in
all subjects and produced HCV core-speciﬁc CTL responses in
peripheral blood mononuclear cells from 15 of 25 patients. Phase
II studies to determine vaccine efﬁcacy are expected to com-
mence in the near future.
Virosome-based HCV vaccines
Pevion Biotech have announced the start of phase I clinical test-
ing of its virosome-based hepatitis C virus (HCV) vaccine in
December 2006. The vaccine is based on a combination of the
PeviPRO and PeviTER platforms that utilize synthetic HCV pep-
tide antigens. A Phase I single-blinded, randomised, placebo con-
trolled, dose escalating study of one virosome formulated CD4
and two virosomes formulated CD8 HCV vaccine components
(PEV2A and PEV2B) administered to healthy adult volunteers
have been registered with clinicaltrials.gov in March 2007 (Table
2). However, to date the results of this trial have not yet been
published.
Tarmogens: globeImmune GI-5005
Tarmogens are a novel development in immunotherapeutic vac-
cines that consist ofwhole heat-killed recombinant Saccharomyces
cerevisiae yeast that have been geneticallymodiﬁed to express one
or more protein targets, including viral proteins. Tarmogens are
avidly taken up by dendritic cells and stimulate both innate and
speciﬁc cellular immune responses [13]. This technology has now
been applied to HCV with the development of a vaccine candidate
(GI-5005a) that encodesa core-NS3 fusion [56](Fig. 1). This vaccine
induces potent HCVNS3 and core speciﬁc T cell responses in vacci-
nated mice [56].
A Phase 1b double-blind, placebo-controlled, dose-escalation
therapeutic trial study of GI-5005-01 evaluated the subcutaneous
administration of 7 doses of GI-5005 as a monotherapy. There
were no dose limiting serious adverse events (SAEs) reported.
Patients receiving GI-5005 had viral load reductions of up to 1.4
log10 while subjects in the placebo group had HCV RNA reduc-
tions <0.75 log10. Normalisation of the ALT was observed in up
to 50% of patients receiving the highest vaccine dose compared
to only 11% in the lowest dosing group and 0% in the placebo
group. HCV speciﬁc CD8+ T cell responses were also observed in
GI-5005 treated subjects, but not placebo subjects [54,128].
A Phase 2 trial comparing the virological response rates of
pegylated interferon/ribavirin (SOC) with and without G1-
5005a in patients infected with HCV genotype 1 has commenced.
Patients in the triple therapy arms were up to 12% more likely to
achieve an early virological response (EVR) than those receiving
SOC alone [85]. .A subsequent Phase 2b study in genotype 1 inter-
feron-naïve patients GI-5005 administered with SOC increased
the end of treatment response to 74% from 59% and SVR from
58% from 48% compared with SOC alone [63,95].
Vaccination with HCV E1 protein (innogenetics/genImmune)
In 2003, a pilot trial from Belgium was published suggesting that
therapeutic vaccination of chronic hepatitis C patients with a
135aa C-terminally truncated recombinant form of the E1 pro-
tein, formulated on alum may slow down ﬁbrosis progressionJournal of Hepatology 2011although no changes in HCV RNA levels were seen in that trial
[109]. Subsequently, two placebo controlled multicentre trials
were initiated in Europe exploring the effects of two different
doses of HCV E1 on ﬁbrosis progression. In the ﬁrst study patients
received 20 lg E1 and were biopsied after 15 months. The second
trial (T2S-918 study) was a 3-year study in which 122 patients
received 4 courses of 6 injections of 50 lg E1. In both trials,
humoral and cellular immune responses against E1 were induced,
however, the T2S-918 study failed to achieve its primary end-
point of an improvement in ﬁbrosis scores [150]. The programme
was stopped in 2007.Vaccination HCV E1E2/MF59 (Chiron Corp)
The HCV E1E2/MF59 vaccine has undergone further development
in a phase Ib therapeutic trial in conjunction with pegylated
interferon and ribavirin in patients who have previously not
responded to standard therapy. The vaccine was shown to be safe
and in those who developed a ﬁrst phase antiviral effect the addi-
tion of the vaccine enhanced the second phase viral clearance
[27]. This further highlights the potential utility of protein-based
vaccines as adjunctive therapeutic agents.Modiﬁed vaccinia Ankara virus (MVA)-based HCV vaccines: TG4040
TG4040 is a recombinant poly-antigenic T cell vaccine based on a
modiﬁed vaccinia Ankara virus (MVA) that encodes for the HCV
NS3, NS4, and NS5B proteins [44]. The safety and biological activ-
ity of TG4040 in 15 treatment-naïve HCV subjects have been
evaluated in a phase I open-label, multicentre, dose escalation
study (Table 2)[59]. Six of 15 patients received 3 weekly injec-
tions of the vaccine while the remaining 9 patients received a
4th injection at 6 months. HCV-speciﬁc T cell responses were
detected in all patients as early as one week after the ﬁrst
vaccination and were maintained during the 6-month follow-
up. Vaccination reduced HCV viral loads by up to 1.5 log10 and
the strongest vaccine speciﬁc T cell responses were observed in
patients who achieved the greatest viral load reductions [59].DNA based vaccines: ChronVac-C, Tripep AB, Sweden
A further approach to producing a T cell based vaccine has been
the development of DNA vaccines. A T cell vaccine based on a
codon optimized HCV non-structural (NS) 3/4A DNA-gene
expressed under the control of the cytomegalovirus immediate-
early promoter (ChronVac-C) has recently been developed by
Tripep AB (Sweden)(Fig. 1). The vaccine has now entered into a
phase I/IIa clinical trial in HCV genotype 1 infected patients viral
loads <800,000 IU/ml to assess safety and immunogenicity (Table
2)[125]. No severe adverse reactions were observed in any of the
dosing arms. Two patients had viral load reductions of up to 1.2
and 2.4 log10 and the development of HCV-speciﬁc T cell
responses coincided with the time of the viral load reductions
[125]. This trial has provided proof-of-concept for a therapeutic
DNA-based vaccine and has paved the way for the further clinical
development of ChronVac-C as an additional therapeutic
agent to pegylated interferon and ribavirin for the treatment of
HCV.vol. 54 j 1273–1285 1279
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vaccinated HCV-chronically infected individuals in a Phase I
study with a therapeutic vaccine (CIGB-230) containing a combi-
nation of a DNA plasmid expressing HCV structural antigens and
recombinant HCV core protein. The individuals, all non-respond-
ers to previous interferon plus ribavirin treatment, received 6
doses of vaccine by intramuscular injection at 4-week intervals.
Neutralizing antibody and HCV core speciﬁc T cell responses
developed in the majority of patients and although viremia per-
sisted, almost half of the vaccinated individuals developed an
improvement in liver histology with a reduction in ﬁbrosis [2].
The CIGB-230 vaccine, therefore, may hold promise of a potential
therapeutic vaccine for patients chronically infected with HCV.Preclinical vaccine strategies
Recombinant adenoviral HCV vaccines
Recombinant adenoviruses expressing structural and non-
structural proteins of HCV have proven to be valuable tools to
help deﬁne the hierarchy of HCV speciﬁc CD8+ T cell responses
[14,137](Fig. 1). Unlike synthetic peptides, which are able to deli-
ver a limited number of epitopes adenoviral vectors contain com-
plete viral genes, thereby delivering intact HCV proteins and are
not limited by HLA class restriction. Adenoviral vectors encoding
HCV core and NS3 proteins are able to stimulate protective HCV1280 Journal of Hepatology 2011speciﬁc cellular immune responses [3,93] and when co-adminis-
tered with an IL12 cytokine expression plasmid produces highly
efﬁcient cytotoxic CD8+ T cell responses [93]. These features
make adenoviral-HCV vectors attractive T-cell based vaccine
candidates.
Recently, investigators have used an adenoviral serotype 6
vector to construct a recombinant adenoviral HCV vaccine
expressing the viral NS3 to 5B proteins [19,39]. This vaccine
induced broad, cross reactive HCV speciﬁc CD8+ T cell responses
in mice and rhesus macaques that are not suppressed by pre-
existing adenovirus 5 immunity. In an extension of these initial
studies, Folgori and coworkers investigated a prime boost strat-
egy in ﬁve chimpanzees that were immunized with two doses,
four weeks apart of a replication-deﬁcient serotype 6 adenovirus
encoding HCV NS3-NS5B. At week 25 the chimpanzees were vac-
cinated with a replication-deﬁcient serotype 24 adenovirus
encoding the same HCV antigens. This was followed by three
intramuscular doses of a recombinant NS3-NS5B DNA vaccine
before challenging the chimpanzees with a heterologous HCV
inoculum. Potent HCV speciﬁc peripheral and intrahepatic CD8+
T cell responses were induced by vaccination and these were
accompanied by the clearance of HCV in 4 of the 5 challenged
chimpanzees. Vaccination also resulted in multi-speciﬁc T cell
responses against several viral proteins, with the strongest
responses directed against NS3 [43]. The success of these recom-
binant adenovirus vaccines provides promise for the develop-
ment of effective therapeutic vaccines for HCV. The
immunogenicity of the vaccine is now being tested further in
healthy volunteers [6].Modiﬁed vaccinia Ankara virus (MVA)-based HCV vaccines
Another approach to the development of HCV therapeutic vac-
cines has been the use of modiﬁed vaccinia Ankara (MVA) viruses
engineered to encode HCV speciﬁc genes. One such vaccine
encoding the HCV NS3-4-5B genes has been tested in HLA-class
I transgenic mice and shown to produce strong long lasting
cross-reactive HCV speciﬁc CD8+ and CD4+ T cells. These
responses could be readily boosted by an additional dose of vac-
cine given after 6 months, suggesting that the vaccine is able to
induce effective memory T cell responses [44].
In a separate study chimpanzees were vaccinated with DNA
plasmids encoding HCV core-E1-E2 and NS3 followed by booster
immunizations with recombinant MVA encoding core-E1-E2 and
NS3 genes [123]. This DNA prime-MVA boost immunization
induced strong Th1- and Th2-cytokine responses together with
strong HCV speciﬁc CD8+ T cell responses. In addition, all animals
achieved high HCV-speciﬁc antibody tires after the prime-boost
combination, but not with the DNA prime alone. A subsequent
challenge with a chimpanzee adapted heterologous virus demon-
strated that the DNA prime-MVA boost was associated with the
control of HCV viremia in the acute stage but unfortunately did
not protect against chronic infection [123]. This highlights the
induction of T-cell responses alone may be insufﬁcient for the
prevention of chronic HCV persistence.HCV virus-like particles (VLP’s)
A HCV VLP based vaccine would make it possible to deliver
important neutralising antibody and core speciﬁc T cell epitopes
in a single vaccine construct that will most closely resemblevol. 54 j 1273–1285
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mature virions antigenically (Fig. 1). The development of an HCV
VLP-based vaccine strategy is also supported by other examples
of VLP based vaccines that have now been successfully licensed
for persistent viral infections, such as hepatitis B virus [67,112]
and human papilloma virus [49]. Although both vaccines induce
cell-mediated immune responses the protective efﬁcacy of these
vaccines relies on their ability to induce long lasting neutralising
antibody.
Insect cell-derived HCV VLPs have produced encouraging
results for HCV vaccine design [11,12,105,134]. However, insect
cell-derived E2 antigens are not able to stimulate a protective
antibody response in primates [22,124] and methods to improve
their immunogenicity will be necessary. HCV VLPs contain poten-
tially neutralising epitopes that are present in the native protein
sequence of both the E1 and E2 proteins [53,84,101,143,144]. An
important feature of HCV VLPs is that cross protective neutralis-
ing epitopes will be present on the surface of the VLPs as part of
AR3 [84]. Immunisation with heterodimers of recombinant E1
and E2 proteins has been shown to protect chimpanzees against
challenge with homologous virus [22]. However, it is unknown
whether heterodimers of recombinant E1 and E2 will successfully
reproduce important cross-neutralising regions like AR3. Unlike
linear recombinant E1 and E2 proteins and synthetic peptides,
HCV VLPs are the most likely vaccine candidate to faithfully
reproduce this important antigenic region. Also, in both mice
and non-human primates HCV VLPs are superior in immunoge-
nicity compared to DNA or recombinant envelope protein vac-
cines [12]. A HCV VLP vaccine based on a single genotype has
been shown to induce cross-protective neutralisation of HCV
[100,105]. It may, therefore, be expected that a vaccine that
includes VLPs of genotypes 1a, 1b, and 3a should induce broad
cross protective immune responses.
HCV VLPs provide a promising vaccine candidate because they
induce humoral and cellular responses against HCV structural
proteins [12,105]; bind NAb against HCV [134]; stimulate the
maturation of human dendritic cells [7]; elicit protective CTL
responses in mice against recombinant vaccinia viruses encoding
structural proteins of HCV [7,105]; elicit protective CTL responses
against HCV in chimpanzees [35] and have superior immunoge-
nicity compared to recombinant proteins and DNA vaccines
[64,86,105]. With so many favourable immunological character-
istics further development of a preventive HCV VLP based vaccine
appears warranted.Recombinant proteins
Recombinant envelope glycoproteins had shown early promise as
vaccine candidates because of their ability to induce protective
neutralising antibody responses in chimpanzees, although this
was only directed against the homologous virus [22]. In addition,
E1 and E2 glycoproteins expressed in insect, yeast, and bacteria
are less effective at inducing protective antibody responses than
glycoproteins produced in mammalian cells [124]. Attempts to
improve the immunogenicity of a HCV envelope gpE1/gpE2 vac-
cine have included the addition of an oil water adjuvant MF59
together with a CpG oligonucleotide (Chiron Corp). The vaccine
prevented the development of chronic infection in chimpanzees
after heterologous viral challenges [61,146].
A recombinant core polyprotein vaccine produced in yeast
formulated in ISCOMATRIX adjuvant [118] has recently been
tested in rhesus macaques and shown to induce strong long-livedJournal of Hepatology 2011CD4+ and CD8+ T-cell responses [118]. A second vaccine consist-
ing of a recombinant HCV core-NS3-NS4-NS5a-NS5b polyprotein
adjuvanted in MF59 has also been shown to induce broad prolif-
erative CD4+ and CD8+ T cell responses against the core and NS
proteins in mice [146].
In an attempt to improve the strength and breadth of antibody
and cellular immune responses against HCV a recent study inves-
tigated a prime-boost vaccination strategy [90]. Mice immunised
with recombinant E1E2 glycoproteins adjuvanted with MF59
containing the CpG oligonucleotide 7909 or a recombinant NS3-
4-5 polyprotein adjuvanted with ISCOMATRIX developed strong
CD4+ T but not CD8+ T-cell responses. In contrast immunization
of mice with defective chimeric Venezuelan equine encephalitis
and Sindbis (VEE/SIN) viruses encoding HCV gpE1/gpE2 or NS3–
NS4–NS5 produced strong CD8+ T-cell but low CD4+ T helper
responses. However, by ﬁrst priming with adjuvanted viral pro-
teins followed by boosting with the chimeric alphavirus-HCV
vaccines it was possible to induce strong CD8+ and CD4+ T cell
responses against the respective viral proteins. First priming mice
with MF59-CpG-adjuvanted E1E2 followed by a VEE/SIN-E1E2
boost induced strong cross-neutralising antibodies [90]. These
prime-boost vaccines may hold promise for the development of
a preventive HCV vaccine.
Synthetic peptide vaccines
Studies using synthetic peptides have provided important
insights into important protective epitopes. Both humoral and
cellular immune responses to HCV have been produced with
peptide vaccines [38,53,69,78,111,143,144]. An approach aimed
at delivering multiple neutralising epitopes involved the poly-
merisation of single vaccine peptides representing potentially
cross-neutralising epitopes into synthetic polymer vaccines that
also included a promiscuous T-helper epitope and a lipid moiety
as an adjuvant [144]. This self-adjuvanting vaccine induced cross-
neutralising antibodies in mice and although promising, the titres
of neutralising antibody to individual viral epitopes were rela-
tively low.
Synthetic lipopeptides representing HCV speciﬁc MHC class I
epitopes have also been shown to induce strong CD8+ T cell
response in rodents, although this response is dependent on the
presence of covalently linked helper-T cell epitopes [111]. The
increased immunogenicity of lipopeptides containing both T
helper and CD8+ epitopes may be related to their increased
uptake by antigen presenting cells [157]. However, peptide strat-
egies based on delivering a limited number of epitopes are unli-
kely to be broadly cross protective for a virus like HCV.Conclusions
HCV has a propensity to cause chronic infection, however, it is
possible to develop robust cellular and humoral immune
responses capable of resolving infection. An effective vaccine will
need to reproduce such broad immune responses in order to
ensure that viral clearance will occur. By better understanding
the correlates of an effective immune response it will be possible
to develop effective preventive and therapeutic vaccine strate-
gies. However, HCV has evolved several mechanisms to evade
the host immune response in order to sustain its own persistence.
In addition to these well-developed viral escape adaptations, avol. 54 j 1273–1285 1281
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vaccine that delivers relatively limited humoral and cellular
immune responses could select neutralization escape variants
or result in skewing T cell repertoires leading to viral escape, par-
ticularly following challenge with heterologous virus [29].
In addition to these concerns to date only a few vaccine can-
didates have progressed to phase I/II trials. Published data on
both the efﬁcacy and safety of these vaccines is limited. However,
with several different vaccine approaches in various stages of
development it appears inevitable that the most promising of
these vaccines candidates will enter into clinical trials. For ther-
apeutic vaccines novel approaches including combination ther-
apy with pegylated interferon and ribavirin [63] or possibly
with the newly developed DAAs [76,94,140] may prove to be
more effective approaches for the treatment of patients who fail
to respond to currently available treatments. With the enormous
global burden of disease posed by hepatitis C and the continuing
transmission of HCV there is a genuine need for an effective vac-
cine for this disease. Success in developing effective vaccines for
HCV will require a strongly committed effort by both research
laboratories and industry partners alike.Conﬂict of interest
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